Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Inderes illustration

Adgang til aktieinformation, aktienyheder, selskabsledelser og analytikere.

Vores filosofi er, at god aktieinformation tilhører alle.

Opret en brugerLog ind
 
OMXCPI-0,62%
OMXC25+0,56%
OMXHPI+0,07%
LEDIBOND+9,92%
RBLN B+8,65%
WMA+6,45%
WIRTEK-7,32%
ACT-15,38%
GREENH-48,06%
 

NTG (One-pager): Acquisitions support revenue growth in Q1 2025 while market weakness squeezes margins

NTG Nordic Transport Group

Columbus (One-pager): Margin improvement despite growth challenges in Q1 2025

Columbus

ISS (One-pager): Guidance maintained after Q1 trading update and share buybacks continue

ISS

TORM (One-pager): Guidance narrowed toward mid-point amid stabilizing markets

Torm

Gabriel Q2'2024/25: Earnings improving but still risks to overcome

Gabriel Holding

GomSpace (One-pager): Gearing up to catch increased opportunities from a solid footing

GomSpace Group

Spar Nord (One-pager): Reports Q1 2025 results as we await a possible delisting

Spar Nord Bank

Curasight (One-pager): Funding of pipeline

Curasight
Anbefalet
Selskabspræsentationer
Selskabsmeddelelser
Eksterne analyser
ViserAlle regioner, Alle indholdstyper
Canatu AGM | CEO's review 15.5.2025
Videofor 1 time siden

Canatu AGM | CEO's review 15.5.2025

Review by CEO Juha Kokkonen from Canatu's Annual General Meeting on May 15, 2025.

Canatu
Scandinavian Medical Solutions: Udfordrende H1 2024/25 på indtjeningssiden trods omsætningsvækst på 20%
Analytikerkommentarfor 3 timer siden af
Kasper Lihn

Scandinavian Medical Solutions: Udfordrende H1 2024/25 på indtjeningssiden trods omsætningsvækst på 20%

Scandinavian Medical Solutions har her til morgen aflagt halvårsrapporten for 2024/25, der dækker perioden 1. oktober 2024 til 31. marts 2025. Trods en omsætningsvækst på 20% faldt selskabets EBITDA til DKK 0,6 mio.

Scandinavian Medical Solutions
Hafnia (One-pager): Markets stabilize in Q1 2025 but at lower levels
Analysefor 3 timer siden af
Philip Coombes, Rasmus Køjborg

Hafnia (One-pager): Markets stabilize in Q1 2025 but at lower levels

Read the latest Hafnia One-pager update following the Q1 2025 results. The One-pager includes a brief company profile, a market update on product tankers, the latest financial performance, and valuation perspectives relative to peers. It also outlines several key investment risks and reasons to consider Hafnia as an investment case.

Hafnia

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Dagens aktienyheder 16/05: Ascelia Pharma, Scandinavian Medical Solutions, Wirtek og Aktier med Friis
Analytikerkommentarfor 4 timer siden

Dagens aktienyheder 16/05: Ascelia Pharma, Scandinavian Medical Solutions, Wirtek og Aktier med Friis

Dagens aktienyheder med Scandinavian Medical Solutions, Ascelia Pharma, Wirtek og Aktier med Friis

Scandinavian Medical SolutionsWirtekAscelia Pharma
Ascelia Pharma: Q1 report with positive Outcome of Orviglance FDA Meeting
Analytikerkommentarfor 4 timer siden af
Claus Thestrup

Ascelia Pharma: Q1 report with positive Outcome of Orviglance FDA Meeting

The company today published its financial results for the first quarter of 2025. The most significant event during the quarter was the outcome of the planned meeting with the U.S. Food and Drug Administration (FDA).

Ascelia Pharma
Orthex Q1'25: Export slump turned out to be deeper than expected
Analysefor 5 timer siden af
Thomas Westerholm

Orthex Q1'25: Export slump turned out to be deeper than expected

Orthex's Q1 figures were disappointing, as credit risk management, fewer campaigns than in the comparison period, and the impact of Finnish strikes pushed revenue into decline and earnings well below the comparison period.

Orthex
Analytikerkommentarfor 5 timer siden af
Thomas Westerholm

Solar Foods' agreement with KelpEat is a step towards strengthening Solein's recognition

Due to KelpEat's small scale, the news has a limited impact on Solar Foods' investment story, but in our view, it is a step in the right direction to strengthen Solein's recognition in the key US market.

Solar Foods
Björn Borg Q1'25: Solid quarter, but the valuation has run ahead
Analysefor 5 timer siden af
Lucas Mattsson

Björn Borg Q1'25: Solid quarter, but the valuation has run ahead

Björn Borg delivered a solid Q1 report, broadly in line with our expectations. As a result, we are maintaining our estimates largely unchanged. However, despite the good Q1 performance, the share price has risen nearly 20% since our last update. At current valuation levels, we view the risk/reward profile as less attractive. Consequently, we turn to a Reduce recommendation (prev. Accumulate) but maintain our target price of SEK 55 per share.

Björn Borg
Metacon Q1'25: Strong quarter with good order momentum
Analysefor 6 timer siden af
Lucas Mattsson

Metacon Q1'25: Strong quarter with good order momentum

Overall, Metacon’s Q1 report was better than expected, and the company has continued to grow its order intake since the end of the quarter, supporting our estimates for sustained growth. That said, we acknowledge the significant risks and uncertainties regarding the company’s ability to consistently secure large orders and maintain sufficient working capital to fulfill them. While liquidity is expected to remain tight until June/July 2025, when we anticipate the release of a significant portion of restricted cash tied to previously announced orders, we believe Metacon is well-positioned to secure short-term project financing on reasonable terms, if needed. With improved near-term revenue visibility, where our 2025 revenue estimates are largely “secured” by the existing order book, we believe the current valuation offers an attractive risk/reward profile. As a result, we reiterate our Accumulate recommendation with an increased target price of SEK 0.23 (was SEK 0.16), mainly due to an upward revision of our estimates.

Metacon
NIBE Q1'25: We are waiting for better entry opportunities
Analysefor 7 timer siden af
Lucas Mattsson

NIBE Q1'25: We are waiting for better entry opportunities

NIBE’s Q1 result was operationally largely in line with our expectations, and we made only minor upside revisions to our short-term earnings estimates. The company's outlook and market indicators continue to show signs of a recovery in the destocking situation. However, a meaningful recovery is likely to take time to materialize due to a slow recovery in consumer confidence and purchasing power, as well as in the new-build market. In our view, short-term drivers remain weak, and the stock is already sufficiently priced in for high earnings growth (2025e P/E: 31x). As a result, we reiterate our Reduce recommendation and our target price to SEK 40.0 per share.

Nibe Industrier
Gabriel- Video med præsentation af regnskabet for 2. kvartal 2024/25
Analytikerkommentarfor 21 timer siden af
Rasmus Køjborg

Gabriel- Video med præsentation af regnskabet for 2. kvartal 2024/25

Fredag i sidste uge havde vi fornøjelsen at afholde event med Gabriel, hvor CEO Anders Hedegaard Petersen præsenterede regnskabet for 2. kvartal 2024/25, og kom omkring den seneste udvikling i både de fortsættende og ophørende aktiviteter. Fik du ikke set med kan du se optagelsen her.

Gabriel Holding
TORM - Video med præsentation af regnskabet for 1. kvartal 2025
Analytikerkommentarfor 21 timer siden af
Rasmus Køjborg

TORM - Video med præsentation af regnskabet for 1. kvartal 2025

Fik du ikke set med i sidste uge, hvor TORM's CFO Kim Balle præsenterede regnskabet for 1. kvartal 2025, har du muligheden for at se optagelsen her.

Torm
Skjern Bank - Video med præsentation af regnskabet for 1. kvartal 2025
Analytikerkommentarfor 21 timer siden af
Rasmus Køjborg

Skjern Bank - Video med præsentation af regnskabet for 1. kvartal 2025

Se eller gense vores præsentation fra sidste uge med Skjern Bank, hvor bankdirektør Per Munck gennemgår regnskabet for 1. kvartal 2025.

Skjern Bank
ExpreS2ion Biotechnologies - Presentation of Q1 2025 report (Recording)
Analytikerkommentarfor 21 timer siden af
Michael Friis

ExpreS2ion Biotechnologies - Presentation of Q1 2025 report (Recording)

Today, ExpreS2ion Biotechnologies’ CEO, Bent Frandsen, presented the results for the first quarter of 2025, provided further insights into the recent pipeline developments, and shared the latest updates on partnerships aimed at commercializing the company’s technology platform

ExpreS2ion Biotech Holding
DFDS – Præsentation af regnskabet for 1. kvartal 2025
Videopræsentationfor 22 timer siden

DFDS – Præsentation af regnskabet for 1. kvartal 2025

Se med når CEO i DFDS – Torben Carlsen – præsenterer regnskabet for 1. kvartal 2025 og dermed også løfter sløret for hvordan året er startet for DFDS. Præsentationen finder sted som et online event - torsdag d. 15. maj kl. 15.00 - hvor der er mulighed for at høre ledelsens udlægning af året, og blive klogere på hvad vi kan forvente os ind i resten af 2025.

DFDS
Anora: Main wine competitor Viva Wine reports solid Q1 and acquisition in the Netherlands
Analytikerkommentarfor 23 timer siden af
Rauli Juva

Anora: Main wine competitor Viva Wine reports solid Q1 and acquisition in the Netherlands

Viva Wine, the main competitor of Anora's Wine segment, announced its Q1 result on Thursday. Although the timing of Easter weighed on Viva's performance as well, the company continued to gain market share in the Nordic countries.

Anora Group
Wirtek (One-pager): Challenging market conditions - but signs of progress with growth in international markets and in the Energy business
Analysefor 23 timer siden af
Kasper Lihn, Victor Skriver

Wirtek (One-pager): Challenging market conditions - but signs of progress with growth in international markets and in the Energy business

Yesterday, Wirtek reported its Q1 2025 results. Despite challenging market conditions and a decline in revenue and EBITDA, the company maintained its full-year 2025 guidance. We have updated our investment case one-pager following the recent results and news.

Wirtek
RTX – Præsentation af kvartalsregnskabet for Q2 2024/25
Videopræsentationi går

RTX – Præsentation af kvartalsregnskabet for Q2 2024/25

RTX ventes at offentliggøre sit kvartalsregnskab for Q2 2024/25 – d. 13. maj 2025. Ugen efter - torsdag d. 15. maj kl. 11.30 – har vi fornøjelsen at indbyde til en gennemgang af regnskabet med ledelsen fra RTX, som også vil svare på spørgsmål fra publikum.

RTX
Analysei går

Inderes Group - April sales well in line - SEB

Inderes reported April sales growth of 8% and the sales were in line with our expectation. The growth was supported by the timing of AGM season. All in all, the monthly report should not trigger any material estimate revisions. We are forecasting somewhat slower sales for the coming months & quarters. Looking toward the year end, the IPO activity and the progress in Sweden are the key factors that could cause estimate revisions we think.

Inderes
Dagens aktienyheder 15/05: Hafnia, MapsPeople og ExpreS2ion
Analytikerkommentari går

Dagens aktienyheder 15/05: Hafnia, MapsPeople og ExpreS2ion

Dagens aktienyheder med Hafnia, MapsPeople og ExpreS2ion

MapsPeopleExpreS2ion Biotech HoldingHafnia

Seneste analyser

Hafnia (One-pager): Markets stabilize in Q1 2025 but at lower levels
Hafnia
16.05.2025
Orthex Q1'25: Export slump turned out to be deeper than expected
Akkumulér
Orthex
16.05.2025
Björn Borg Q1'25: Solid quarter, but the valuation has run ahead
Reducer
Björn Borg
16.05.2025
Metacon Q1'25: Strong quarter with good order momentum
Akkumulér
Metacon
16.05.2025
NIBE Q1'25: We are waiting for better entry opportunities
Reducer
Nibe Industrier
16.05.2025
Vis alle

Trending

Dagens aktienyheder 09/05: Gabriel, GomSpace, ALK, Gubra og BioPorto
09.05.2025 Analytikerkommentar
Ratos AB: Ratos company HL Display acquires Allied POS
02.12.2022 Pressemeddelelse
DFDS – Præsentation af regnskabet for 1. kvartal 2025
07.04.2025 Videopræsentation
GrønlandsBANKEN – Præsentation af regnskabet for 1. kvartal 2025
22.04.2025 Videopræsentation
NTG – Præsentation af regnskabet for 1. kvartal 2025
22.04.2025 Videopræsentation

Kommende selskabspræsentationer

Scandinavian Medical Solutions - Præsentation af H1 2024/25
19.05.2025, 13.00 Scandinavian Medical Solutions
MapsPeople – Presentation of Q1 2025 report
21.05.2025, 14.00 MapsPeople
SP Group – Præsentation af regnskabet for 1. kvartal 2025
23.05.2025, 10.00 SP Group
SP Group – Presentation of the quarterly report for Q1 2025
23.05.2025, 15.00 SP Group
Impero – Præsentation af Q1 2025
26.05.2025, 11.00 Impero
Vis alle
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.